Ab Initio Biotherapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $12M
Latest Deal Amount

Ab Initio Biotherapeutics General Information

Description

Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-access cellular targets. The company's platform allows for targeting multi-transmembrane and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders, enabling doctors to optimize the solubility and stability of drugs.

Contact Information

Website
www.aibio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 280 Utah Avenue
  • South San Francisco, CA 94080
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ab Initio Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Jul-2019 $12M 000 0000 Completed Generating Revenue
3. Corporate 13-Dec-2016 000 Completed Startup
2. Angel (individual) $2M $2M Completed Startup
1. Accelerator/Incubator 03-Mar-2015 Completed Startup
To view Ab Initio Biotherapeutics’s complete valuation and funding history, request access »

Ab Initio Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-acce
Biotechnology
South San Francisco, CA
000
000 0000-00-00
000000&0 000

0000000

im ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000 000000000
Maastricht, Netherlands
00 As of 0000
000.00
0000000000 000.00

000000 0

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia des
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ab Initio Biotherapeutics Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands 00 000.00 0000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
00000000 Formerly VC-backed Paris, France 00 000.00 000000000 000.00
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 0000 00000000 0000
You’re viewing 5 of 24 competitors. Get the full list »

Ab Initio Biotherapeutics Executive Team (6)

Name Title Board Seat Contact Info
Robert Booth Ph.D Co-Founder & Executive Chairman
You’re viewing 1 of 6 executive team members. Get the full list »

Ab Initio Biotherapeutics Board Members (1)

Name Representing Role Since
Robert Booth Ph.D Self Co-Founder & Executive Chairman 000 0000
To view Ab Initio Biotherapeutics’s complete board members history, request access »

Ab Initio Biotherapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer Corporation Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
To view Ab Initio Biotherapeutics’s complete investors history, request access »